Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (10)

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

2015

  1. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry

    Leukemia, Vol. 29, Núm. 9, pp. 1875-1881

2014

  1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201

2013

  1. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

    Journal of Clinical Oncology, Vol. 31, Núm. 7, pp. 916-922

2012

  1. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome

    Cancer, Vol. 118, Núm. 1, pp. 127-133

  2. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes

    British Journal of Haematology, Vol. 159, Núm. 3, pp. 311-321

  3. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

    Leukemia Research, Vol. 36, Núm. 3, pp. 287-292

2011

  1. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

  2. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

    Cancer, Vol. 117, Núm. 24, pp. 5529-5537

1996

  1. Myelodysplastic syndromes

    Critical Reviews in Oncology/Hematology, Vol. 23, Núm. 1, pp. 57-93